首页> 美国卫生研究院文献>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America >Safety and Efficacy of a Novel Vaginal Anti-infective TOL-463 in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized Single-blind Phase 2 Controlled Trial
【2h】

Safety and Efficacy of a Novel Vaginal Anti-infective TOL-463 in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized Single-blind Phase 2 Controlled Trial

机译:新型阴道抗感染药TOL-463在治疗细菌性阴道病和念珠菌性念珠菌病中的安全性和有效性:随机单盲2期对照试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundBacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) present serious reproductive health risks and management challenges, with poor control attributed to survival of treatment-resistant biofilm communities. Boric acid is used in various regimens for non-albicans VVC and recurrent BV. We investigated safety and efficacy of a novel boric acid–based vaginal anti-infective with enhanced antibiofilm activity (TOL-463) in treating BV and VVC.
机译:背景细菌性阴道病(BV)和念珠菌性外阴阴道炎(VVC)带来了严重的生殖健康风险和管理挑战,控制不力归因于耐药性生物膜群落的生存。硼酸用于非白色VVC和复发性BV的各种方案中。我们研究了一种新型的基于硼酸的阴道抗感染剂,具有增强的生物膜活性(TOL-463),用于治疗BV和VVC的安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号